Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 17, 2026

Earnings live: eToro surges after Q4 profit beat, Medtronic stumbles, DTE Energy pops

View original at finance.yahoo.com
Earnings live: eToro surges after Q4 profit beat, Medtronic stumbles, DTE Energy pops The fourth quarter earnings season is entering the final stretch…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cisco raised full-year EPS guidance to $3.00-$3.08 on revenue of $61.2-$61.7 billion, below Street estimates of $3.12 EPS on $62.1 billion revenue

    80% confidence
  • Coinbase expects Q1 subscription and services revenue of $550 million to $630 million, compared to $710 million to $790 million in Q4

    80% confidence
  • 74% of S&P 500 companies have reported results as of Feb. 13, with blended earnings growth at 13.2%

    80% confidence
  • The Extra Value Meal deal is fundamental in the current environment; many locations would keep it even as corporate support is pulled back in Q1

    80% confidence
  • Coinbase has seen $420 million of transaction revenue in Q1 through Feb. 10

    80% confidence
  • Analysts were expecting an 8.3% jump in earnings per share heading into Q4 reporting, down from Q3's 13.6% growth rate

    80% confidence
  • Equinix issued strong annual revenue guidance on the back of continued artificial intelligence demand

    80% confidence
  • Baxter forecast 2026 annual profit below Wall Street estimates, citing persistent problems from hurricane-related issues at manufacturing plant

    80% confidence
  • Coinbase customer funds are safe despite exchange issues

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com